Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open Label, Randomized, Multicenter Trial Comparing Noncontrast MRA vs. Ferumoxytol Vascular Enhanced MRI for Detection of Stenosis or Occlusion of the Aortoiliac and Superficial Femoral Arteries in PAD Subjects Scheduled for DSA

NCT00707876 is registered in ClinicalTrials.gov with AMAG Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00707876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00707876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open Label, Randomized, Multicenter Trial Comparing Noncontrast MRA vs. Ferumoxytol Vascular Enhanced MRI for Detection of Stenosis or Occlusion of the Aortoiliac and Superficial Femoral Arteries in PAD Subjects Scheduled for DSA
Lead sponsor
AMAG Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 1, 2008
Completion date
August 15, 2020
Enrollment
119 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral arterial disease (pad)